A crossover comparison study on overactive bladder: vibegron versus mirabegron

A crossover comparison study on overactive bladder: vibegron versus mirabegron - Comparison of two beta 3-adrenoreceptor agonist

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000035525

Enrollment

Registered

2019-01-11

Start date

2019-01-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

overactive bladder

Interventions

Vibegron Mirabegron

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Male and female patients with OAB symptoms

Exclusion criteria

Exclusion criteria: Patients who have severe heart and liver dysfunction, pregnant women

Design outcomes

Primary

Measure	Time frame
patient preference for the drugs, and the reasons	—

Secondary

Measure	Time frame
Clinical efficacy using with questionnaires	—

Countries

Japan

Contacts

Public ContactTakahiro Suetomi

Ibaraki Seinan Medical Center Hospital Department of Urology

Hinyouki-suetomi@seinan-mch.or.jp0280-87-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026